Last reviewed · How we verify
Reformulated Raltegravir
Reformulated raltegravir is an integrase strand transfer inhibitor that prevents HIV from integrating its genetic material into the host cell's DNA.
Reformulated raltegravir is an integrase strand transfer inhibitor that prevents HIV from integrating its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.
At a glance
| Generic name | Reformulated Raltegravir |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Integrase strand transfer inhibitor (INSTI) |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Raltegravir blocks the catalytic activity of HIV integrase, the enzyme responsible for inserting viral DNA into the human genome. By inhibiting this critical step in the HIV replication cycle, the drug prevents establishment of persistent infection. The reformulation aims to improve pharmacokinetic properties, bioavailability, or dosing convenience compared to the original formulation.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- HIV-1 infection as part of combination antiretroviral therapy
Common side effects
- Nausea
- Diarrhea
- Headache
- Insomnia
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reformulated Raltegravir CI brief — competitive landscape report
- Reformulated Raltegravir updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI